首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach**
Authors:Dr Milan Sencanski  Dr Vladimir Perovic  Dr Jelena Milicevic  Dr Tamara Todorovic  Dr Radivoje Prodanovic  Dr Veljko Veljkovic  Dr Slobodan Paessler  Dr Sanja Glisic
Institution:1. Laboratory of Bioinformatics and Computational Chemistry Institute of Nuclear Sciences Vinca National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12–14, 11000 Belgrade, Serbia;2. Faculty of Chemistry, University of Belgrade, Studentski Trg 12–16, 11000 Belgrade, Serbia;3. Biomed Protection, Galveston, TX 77550 USA;4. Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550 USA

Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555 USA

Abstract:In the current pandemic, finding an effective drug to prevent or treat the infection is the highest priority. A rapid and safe approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 PLpro promotes viral replication and modulates the host immune system, resulting in inhibition of the host antiviral innate immune response, and therefore is an attractive drug target. In this study, we used a combined in silico virtual screening for candidates for SARS-CoV-2 PLpro protease inhibitors. We used the Informational spectrum method applied for Small Molecules for searching the Drugbank database followed by molecular docking. After in silico screening of drug space, we identified 44 drugs as potential SARS-CoV-2 PLpro inhibitors that we propose for further experimental testing.
Keywords:drug repurposing  ISM  molecular docking  Papain-like protease  SARS-CoV-2
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号